bluuebunny/crossref_metadata_2025_split huggingface dataset:
698-P: Interoperability as an Important Factor for Achieving the Full Potential of a Digital Diabetes Logbook
Authors: KULZER BERNHARD , HERMANNS NORBERT , VESPER IRIS , SCHAEFER VANESSA L. , SILBERMANN STEPHAN , KOBER JOHANNA , FINKE-GROENE KATHARINA , ROOS TIMM , BINGOL EZGI , EHRMANN DOMINIC 
Published: June 2023

A randomized controlled trial (RCT) has demonstrated the efficacy of a digital diabetes logbook (mySugr) in reducing diabetes distress compared to a control group without such an app. In a sub-group analysis, we analyzed whether those who have paired their glucose meter (glucose values were directly imported into the app) benefit differently than those who manually entered their glucose values. A total of 282 people were randomized to the intervention group using the app for 3 months (2:1 randomization; age: 51.2±14.6 years; 13.1% type 1, 66.7% type 2, 20.2% gestational diabetes). The per protocol population within the intervention group consisted of 232 participants who completed the 3-month follow-up and have used the app on ≥10% of the study days. Analysis of covariance was conducted with diabetes distress at the 3-month follow-up at dependent variable and connected glucose meter (yes/no) as independent variable, controlled for diabetes distress at baseline. Diabetes distress was measured with the Problem Areas in Diabetes (PAID) questionnaire. Within the per protocol population, 134 participants of the intervention group (57.8%) have used a connected glucose meter. Participants with a connected meter had significantly less diabetes distress at follow-up compared to participants who manually entered their glucose values (16.9±1.05 vs. 20.5±1.2, p = 0.027). There was no significant difference in demographic characteristics between the two groups. Participants with a connected meter had significantly more meal logs (3.3±2.2 vs. 2.0±1.2, p = 0.01) on days they have used the app. Overall, the digital diabetes logbook was able to reduce diabetes distress over a 3-month period. This reduction in diabetes distress was more pronounced in participants who used an interoperable glucose meter that automatically transferred glucose data into the app. Interestingly, there seems to be an increased interaction with the app regarding logging of meals in participants with a connected meter.

Disclosure
B.Kulzer: Advisory Panel; Berlin-Chemie AG, Abbott Diabetes, Bayer Inc., Dexcom, Inc., Novo Nordisk, Insulet Corporation, embecta, Research Support; Sanofi, Roche Diabetes Care. D.Ehrmann: Advisory Panel; Roche Diabetes Care, mySugr, Dexcom, Inc., Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. N.Hermanns: Advisory Panel; Insulet Corporation, Research Support; Sanofi-Aventis Deutschland GmbH, Roche Diagnostics, Becton, Dickinson and Company, Speaker's Bureau; Dexcom, Inc., Berlin-Chemie AG. I.Vesper: None. V.L.Schaefer: Employee; Roche Diabetes Care. S.Silbermann: Employee; Roche Diabetes Care. J.Kober: Employee; mySugr. K.Finke-groene: None. T.Roos: None. E.Bingol: Employee; Roche Diabetes Care.

Funding
Roche Diabetes Care GmbH (DC000097)
774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes
Authors: CHAKRAVARTHY MANU , HERNANDEZ MOISES , ELLIOTT MICHAEL , MACIAS ALEJANDRA , HANSEN STIG K. , HOMPESCH MARCUS 
Published: June 2023

GLP-1 and GIP can deliver complementary pharmacology when combined. CT-868 (CT) is a biased dual GLP-1 and GIP receptor modulator that exhibits no arrestin coupling or receptor internalization at either receptor. Its effects on insulin (INS) secretion via graded glucose infusion (GGI), glucose (GLUC) homeostasis in response to a mixed meal tolerance test (MMTT), gastric emptying (GE), and food intake (FI) were investigated in a randomized, double-blind crossover study in 20 overweight and obese adults with T2D split into 2 groups: CT vs placebo (PL), n=7 and CT vs PL vs liraglutide (LI), n = 13, the latter as a fixed 3rd period. Mean age and BMI were 52.2 years and 32.7 kg/m2 with 55% males. Treatments were administered for 4 days to minimize weight loss with 14 days washout between periods. GGI data showed robust INS secretion for CT-868 vs PL [change in ISR/GLUC at GIRmax (pmol/kg/min): CT 1.1 (0.1), PL 0.1 (0.2), LI 1.0 (0.3)]. MMTT based GLUC iAUC0-240 was significantly reduced for CT vs PL [72(46) vs 392(48)mmol/L*min] and numerically lower vs. LI [187(55) mmol/L*min] accompanied by significantly decreased INS iAUC0-240 vs both PL and LI: CT 1178(846), PL 5833(873), LI 4613(1253) mU/L*min. As both CT and LI had similar delayed GE vs PL, the reduced GLUC and INS excursion seen with CT suggests improved INS sensitivity or enhanced INS independent GLUC disposal. CT demonstrated minimal suppression of glucagon during MMTT vs LI that showed glucagon lowering. FI was lower for CT vs PL accompanied by reduction in hunger and appetite as assessed by VAS. There were no significant body weight changes in any treatment period. GI side effects were mostly mild and transient. This data supports a robust weight-independent effect of CT-868 (vs unbiased liraglutide) on glucose disposal with minimal suppression of glucagon. Further delineation of CT-868's longer term effects in overweight and obese patients with both T2D and T1D is underway.

Disclosure
M.Chakravarthy: Employee; Carmot Therapeutics, Inc. M.Hernandez: None. M.Elliott: Employee; Carmot Therapeutics, Inc. A.Macias: None. S.K.Hansen: Board Member; Carmot Therapeutics, Inc. M.Hompesch: Board Member; ProSciento, Consultant; Wiley-Blackwell, Employee; ProSciento, Stock/Shareholder; ProSciento.
849-P: Antidiabetic Effects of TLC-3595, a Selective ACC2 Inhibitor, in ZDF Rats
Authors: VIJAYAKUMAR ARCHANA , MURAKAMI EISUKE , HUSS RYAN S. , SRODA NATALIE , SHIMAZAKI ATSUYUKI , KASHIWAGI YUTO , MYERS ROBERT P. , SUBRAMANIAN MANI , SHULMAN GERALD I. 
Published: June 2023

Background: TLC-3595 is a potent (IC50=14nM), selective, small molecule, allosteric inhibitor of acetyl-CoA carboxylase 2 (ACC2). TLC-3595 provides a novel therapeutic approach for type 2 diabetes (T2D), via reduction in intramyocellular lipid (IMCL) content, that is complementary to approved therapies. Reduced IMCL strongly correlates with insulin sensitivity (IS). Here, we demonstrate antidiabetic effects of TLC-3595 in Zucker Diabetic Fatty (ZDF) rats.
Methods: IMCL was measured by 1H-MRS. T2D progression and IS by hyperinsulinemic-euglycemic clamp were assessed in 30% diet-restricted ZDF rats treated with TLC-3595 (1.67, 5, or 15mg/kg) or pioglitazone (Pio, 0.75mg/kg) daily for 5-12 weeks.
Results: TLC-3595 or an analog caused rapid and sustained IMCL reduction (~50%) in lean and dysmetabolic rodents. TLC-3595 enhanced systemic fatty acid oxidation (increased plasma beta-hydroxybutyrate) and reduced cardiac lipid in ZDF rats. TLC-3595 dose-dependently delayed β-cell failure in ZDF rats and was non-inferior to Pio for reductions in hyperglycemia (15-25% lower glucose AUC) and HbA1c (0.6-1.6% vs. vehicle) (Fig A, B). TLC-3595 improved IS and increased clamp glucose infusion rate by 29%, (Fig C).
Conclusion: TLC-3595 reduced IMCL, improved IS, and delayed T2D progression comparable to Pio in ZDF rats. These data provide strong rationale for evaluation of TLC-3595 to treat insulin resistance and T2D.

Disclosure
A. Vijayakumar: Employee; OrsoBio Inc, Gilead Sciences, Inc. E. Murakami: Employee; OrsoBio. R.S. Huss: Employee; OrsoBio, Inc. Stock/Shareholder; OrsoBio, Inc. N. Sroda: None. A. Shimazaki: Employee; Shionogi & Co. Ltd. Y. Kashiwagi: Employee; Shionogi & Co. Ltd. R.P. Myers: Employee; OrsoBio, Inc. Stock/Shareholder; OrsoBio, Inc. M. Subramanian: Other Relationship; OrsoBio Inc. G.I. Shulman: Other Relationship; AstraZeneca, Merck & Co., Inc., Janssen Research & Development, LLC. Consultant; Novo Nordisk. Other Relationship; iMetabolic Biopharma Corporation, Maze Therapeutics, 89bio, Inc. Consultant; DiCerna Pharmaceuticals, Inc. Other Relationship; Equator Therapeutics, Inc., Generian Pharmaceuticals. Stock/Shareholder; Levels Health, Inc. Other Relationship; Fortress Biotech, Inc. Consultant; Bayer Consumer Care AG, Kriya Therapeutics, Arrowhead Pharmaceuticals, Inc., ESPERION Therapeutics, Inc. Other Relationship; OrsoBio, Aro Biotherapeutics Company.
877-P: Effects of SGLT2 Inhibitors on Gut Microbiota in Japanese Patients with Type 2 Diabetes
Authors: KUSUNOKI MASATAKA , HISANO FUMIYA , MATSUDA SHIN-ICHI , MIYATA TETSURO 
Published: June 2023

SGLT2 inhibitors (SGLT2is) promote urinary glucose excretion, thereby lowering blood glucose. In addition, SGLT2is have been reported to reduce body weight. However, the mechanism underlying the reduction in the body weight induced by SGLT2i remains to be elucidated. In this study, we investigated the effects of SGLT2is on the gut microbiota. A total of 36 Japanese patients with type 2 diabetes received SGLT2is for 3 months, and the prevalences of balance-regulating bacteria (12 types), which regulate the balance of the gut microbiota to maintain health, and balance-disturbing bacteria (6 types), which disturb the balance of the gut microbiota to cause disease, in the feces of the patients before and after 3 months of SGLT2i treatment were determined. Furthermore, the prevalences of short-chain fatty acid-producing bacteria (6 types), which are thought to be involved in body weight gain and weight loss, were also analyzed individually. The SGLT2i treatment was associated with a significant increase of the overall prevalence of the 12 types of balance-regulating bacteria. In addition, significant increases in the prevalences of the short-chain fatty acid-producing bacteria among the balance-regulating bacteria were also observed. However, the SGLT2i treatment had no effect on the balance-disturbing bacteria. Individual analyses of the balance-regulating bacteria revealed that the SGLT2i treatment was associated with a significant increase in the prevalence of Ruminococci, which are balance-regulating bacteria classified as short-chain fatty acid-producing bacteria. In conclusion, SGLT2i treatment was associated with an overall increase in the prevalence of balance-regulating bacteria. Among the balance-regulating bacteria, the prevalences of short-chain fatty acid-producing bacteria increased. Since short-chain fatty acids have been reported to prevent obesity, these results suggest that SGLT2is might induce body weight reduction via their actions on the gut microbiota.

Disclosure
M.Kusunoki: Research Support; Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo, Kaken Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. F.Hisano: None. S.Matsuda: None. T.Miyata: None.
879-P: Cardiorenal Outcomes Associated with the Use of Dapagliflozin Compared with DPP-4 Inhibitors as Add-on Treatment in Uncontrolled DM2 Patients with Failure to Previous Treatment—A Retrospective, Real-Life Evaluation in México
Authors: ESPINOZA-PERALTA DIEGO , HERNANDEZ-ALARCON JIMENA , LOPEZ IRLANDA N. , CETINA-CANTO JOSE , BÚRQUEZ-GONZÁLEZ MARIA E. , PAUL PEDRO V. , BUSTAMANTE GUADALUPE A. , CARLOS GARNICA CUELLAR JUAN , MIRELES-ZAVALA LEONOR G. , JUAREZ-COMBONI SONIA C. , RODRÍGUEZ ARELI M. 
Published: June 2023

Mexico is one of the three countries in Region of Americas with the highest prevalence (14.4%) of DM. We conducted a retrospective study in Mexico and compare Dapagliflozin effect in cardio-renal outcomes and metabolic control compared to DPP4-inhibitors (DPP4i) as added-on therapy in T2DM patients with failure to previous medications.
Objectives: Compare proportion of patients achieving HbA1c below 7%, first appearance of eGFR below 60 ml/min, renal replacement therapy, heart failure hospitalization and death by the end of the 156-week observation period from index date.
Inclusion Criteria: T2DM subjects ≥18 years old with failure to any previous antidiabetic medication and HbA1c% ≥7 that started Dapa or DPP4i as add-on to other antidiabetic drugs from August 2014 to December 2019.
Statistical Methods and Analysis: A propensity score matching model (nearest neighbor algorithm) was used.
Results: Of 1800 subjects, 267 met statistical matching criteria. There were no differences in basal characteristics of age, SBP, Creatinine Clearance, but DAPA group had higher basal HbA1c (8.54±1.45 vs 8.16±1.43, p&lt;0.01). Patients in Dapa compared to DPP4i achieved A1c ≤7% in 49.8% vs 20% (p&lt;0.01) by week 156. Creatinine clearance between groups favored DAPA after week 52 (76.07±18.52 vs 86.40±21.27, p&lt;0.01), and persisted through week 156 (68.19±19.4 vs 88.45±19.73, p&lt;0.01). By week 52, Incidental CKD was present in 5.8% of Dapa group and in 14.8% of DPP4i group, p=0.013 (OR 0.607, 95% IC 0.409-0.901), and by week 156 6.5% DAPA vs 27.6% DPP4i, p&lt;0.01 (OR 0.275, 95% IC 0.191-396). There were no differences in HF hospitalizations.
Conclusion: In patients with uncontrolled T2DM who have failed to previous antidiabetic therapies, the add-on of dapagliflozin significantly provides reductions of HbA1c, microalbuminuria and reduces the risk of CKD compared to DPP4i add-on.

Disclosure
D.Espinoza-peralta: None. S.C.Juarez-comboni: Employee; AstraZeneca. A.M.Rodríguez: Employee; AstraZeneca. J.Hernandez-alarcon: None. I.N.Lopez: None. J.Cetina-canto: None. M.E.Búrquez-gonzález: None. P.V.Paul: None. G.A.Bustamante: None. J.Garnica cuellar: None. L.G.Mireles-zavala: None.
891-P: SGLT2 Inhibitors Use and Diabetic Ketoacidosis in the Inpatient Setting
Authors: ZANKAR SARAH , ARNAOUT AMEL 
Published: June 2023

Background: Current guidelines recommend SGLT2 inhibitors in patients with cardiovascular disease, chronic kidney disease and/or heart failure. Studies have demonstrated early initiation of SGLT2i in stable hospitalized patients to be safe and associated with benefits such as reduced hospitalization. However, SGLT2i are known to lower the threshold for developing diabetic ketoacidosis (DKA) and reported rates with real world use are higher than those seen in randomized controlled trials. There are limited studies evaluating the safe use of SGLT2i in the real world inpatient setting.
Aim: The primary aim of this study is to determine the incidence of DKA in patients with diabetes admitted to hospital and started or continued on an SGLT2i. A secondary aim is to determine risk factors to inpatient SGLT2i associated acidosis and make recommendations for safe initiation in hospital.
Methods: A retrospective chart review was performed on patients with diabetes admitted to a tertiary hospital with anion-gap metabolic acidosis (AGMA) between January 2020-June 2020 (prior to SGLTi being available on hospital formulary) compared to between January 2021-June 2021 (post-formulary). Patients were included if they were started or continued on an SGLT2i during their admission or were on an SGLT2i &lt; 72h prior to admission.
Results: 159 patient charts met our inclusion criteria, with 43.4% (n=69) admitted prior to SGLT2i being available on hospital formulary and 56.6% (n=90) admitted post-formulary. There was a 12.2% (n=11) increase in patients with AGMA with SGLT2i being available on hospital formulary. 41.0% of patients were above the age of 70, and common issues during admission were infection (66.7%), acute kidney injury (44.0%), surgery (23.3%), and/or confusion (23.9%).
Conclusion: Increased use of SGLT2i in hospital resulted in an increase in incidence of inpatient DKA in older patients admitted with infection, AKI, surgery and/or confusion.

Disclosure
S.Zankar: None. A.Arnaout: None.
Performance Evaluation of Grid Connected T-Type Multilevel Inverters
Authors: Kevin ACADINE  , Augustin MPANDA MABWE  , Ahmed EL HAJJAJI  
Published: June 2023

This paper deals with performance of three and five level grid-connected T-type inverters. T-Type structure requires fewer power devices than Neutral-Point-Clamped and Flying-Capacitor inverters for the same power level.First, mathematical model of grid connected T-Type inverters is demonstrated. The PI controller is used to control the d-axis and q-axis currents, respectively. The sine Pulse Width Modulation (PWM) technique is used to control the MOSFET switches. The simulation of the complete system has been performed on MATLAB/Simulink.
Pensamiento crítico VS competencia crítica: lectura crítica
Authors: Jiménez Pérez Elena del Pilar 
Published: June 2023

El pensamiento crítico no es un concepto actual, sin embargo, está tomando especial relevancia en la sociedad de hoy en día gracias, en parte, al problema que supone para el ser humano las fake news y, por extensión, se está comenzando a trabajar de forma sistemática en los centros educativos. De igual forma, el pensamiento crítico también afecta a la comprensión de la información recibida desde un punto de vista emocional, ya que ayuda a ser objetivos y a evitar mal interpretar tanto mensajes orales como escritos. En este sentido, el pensamiento crítico evoluciona a competencia como capacidad de ponerla en práctica, son conceptos paralelos al de comprensión lectora con respecto a la competencia lectora. Además, la mayoría de los tests que se han ido utilizando para acotar el pensamiento crítico son traducciones del inglés que, en algunos casos, resultan ambiguos y confusos de interpretar en español. De ahí la importancia del papel de la comprensión de lo que se lee para poder desarrollar una competencia crítica sólida y solvente. El presente estudio es una revisión de la literatura científica que se propone como objetivo discernir qué es el pensamiento crítico, recogido como una de las capacidades a desarrollar con el alumnado según Europa, como base para la definición de la competencia crítica, así como sus dimensiones, su relación con la lectura y su papel en el aula.
Intervention-related self-defence
Authors: Stefańska Blanka Julita 
Published: June 2023

Abstract
The scholarly and research-focused article examines the content of Article 25 §§ 4 and 5 CC, which was transferred to the new Article 231b §§ 1 and 2 CC of Chapter XXIX of the Criminal Code by means of Act of 20 February 2015 amending the Criminal Code Act and Certain Other Acts. The regulation concerns the intervention-related self-defence, wherein a person acting in self-defence and repelling an attack on another’s good protected by law, while simultaneously protecting public security or order, is granted the same legal protection as public officials. The article analyses the genesis and development of this defence, its legal nature, objectives, conditions for application, the scope of criminal law protection for a person acting within the intervention-related self-defence, the exclusion of this protection, and the relationship between Article 231b § 1 and Article 217a CC. The primary scientific objective is to evaluate the legitimacy of its introduction to the Criminal Code and the correctness of defining the premises for its application and its scope. The aim of the considerations is to demonstrate that this measure, despite the negative assessment of its introduction to the Criminal Code in the doctrine, can play a vital role in ensuring security and public order.
Stepparents’ Upbringing Obligation Towards their Stepchildren
Authors: Lewandowska-Urbanowicz Monika 
Published: June 2023

Abstract
The article explores the issue of reconstructed families, focusing specifically on the roles of individual family members and the processes that occur within such families. Due to the complexity of the above processes, the article concentrates on the deliberations about the stepparent’s upbringing process towards the stepchild, determining its content, scope and role. The article analyses of the stepparent’s duty towards the stepchild, highlighting its normative sources, and assesses this duty in relation to the parental authority of the spouse and the parental authority of the other biological parent outside the reconstructed family. The deliberations presented in the article aim to support the primary thesis of the article that in order for the foster parent’s current custody of the child to be effective, the stepparent’s situation in terms of upbringing obligation should be made independent of the biological parent’ situation, which stems from their parental authority. The article proposes introducing for example, an institution of the so-called “adoptive parent’s care” that would encompass some rights and obligations typical of parental authority and independent of the parental authority of the child’s biological parent. This could serve as an equivalent to the concept of parental responsibility found in English law.
Submission of the Point of Law Which Raises Serious Doubts in Civil Proceedings for the Resolution by the Supreme Court
Authors: Sekuła-Leleno Małgorzata 
Published: June 2023

Abstract
The institution of questions of law, as a result of which the court ruling in the case is bound by the view of the Supreme Court expressed in its resolution, is an exception to the constitutional principle of subordination of judges solely to the Constitution and statues (Article 178(1) of the Constitution of the Republic of Poland).
The point of law which raises serious doubts because divergent interpretation of the same provision exist in the case-law could be submitted when in the opinion of the appellate court each of these interpretations can be adopted in view of its significant legal arguments, and neither the position of the jurisprudence nor the doctrine of law explains which interpretation should be chosen.
The point of law submitted to the Supreme Court for resolution under Article 390(1) of the Code of Civil Procedure must meet three basic requirements. Firstly, the point of law must be of an abstract nature and concern the interpretation of legal provisions, as it is unacceptable to present to the Supreme Court a question of law simply to get an answer on how to settle the case. Secondly, the point of law needs to concern a legal doubt which needs to be clarified in order to examine the legal remedy; in other words, in order to use the right set forth in Article 390(1) of the CCP, a link must exist between the presented point of law and a decision to be made on the merits of the case, and such link needs to be demonstrated through the juridical consistency of the point of law formulated at the outset and the reasons thereto, and through the proper reference to the facts of the case in such generally defined question of law. Thirdly, the point of law to be resolved needs to concern a legal issue which raises serious doubts; if ordinary doubts arise, the court of second instance needs to settle them on its own. The significance of the issue or the discrepancies in the jurisprudence and literature regarding the ways of its resolutions are not per se independent premises for raising a question of law.